Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-1: SPX-101 Inhalation Solution in Cystic Fibrosis
2016-005230-30Phase 2Completed
- Sponsor
- Spyryx Biosciences
- Start
- May 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing SPX-101 with Placebo (2 arms). Primary endpoint: Change from baseline in percent predicted FEV1 (primary). Started May 2017; status: completed.
02
Drugs
SPX-101
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-005230-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005230-30.